-
公开(公告)号：EP3630845A1
公开(公告)日：2020-04-08
申请号：EP18724280.5
申请日：2018-05-22
-
公开(公告)号：EP3319597A1
公开(公告)日：2018-05-16
申请号：EP16736481.9
申请日：2016-07-08
CPC分类号： A61K47/6809 , A61K9/19 , A61K31/4184 , A61K39/3955 , A61K47/183 , A61K47/26 , A61K47/6803 , A61K47/6851 , C07K16/2863 , C07K16/30 , C07K16/32 , C07K2317/24
摘要： The present invention relates to lyophilized compositions comprising antibody-duocarmycin drug conjugates.
-
公开(公告)号：EP3069735B1
公开(公告)日：2018-03-14
申请号：EP16160637.1
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
-
公开(公告)号：EP2791172B1
公开(公告)日：2017-07-19
申请号：EP12821017.6
申请日：2012-12-14
CPC分类号： C07K16/241 , A61K9/0053 , A61K39/00 , A61K2039/505 , A61K2039/54 , C07K16/244 , C07K2317/13 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C12N15/8258
-
公开(公告)号：EP3092010A2
公开(公告)日：2016-11-16
申请号：EP15700117.3
申请日：2015-01-09
IPC分类号： A61K47/48
CPC分类号： A61K47/48384 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/32
摘要： The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueous salt solution, in which non-conjugated antibody is collected in a flow-through fraction, followed by elution of a purified mixture of cysteine-linked antibody-drug conjugates using a 0-100 mM aqueous salt solution.
摘要翻译： 本发明涉及使用疏水相互作用色谱法（HIC）纯化半胱氨酸连接的抗体 - 药物缀合物的混合物的方法，其中非缀合抗体的量在0-40重量％的范围内。 使用0.2-1.5M盐酸水溶液将混合物加载到制备型HIC柱上，其中在流通级分中收集未缀合的抗体，随后使用半胱氨酸连接的抗体 - 药物缀合物的纯化混合物洗脱 0-100mM的盐水溶液。
-
公开(公告)号：EP3525826A1
公开(公告)日：2019-08-21
申请号：EP17780446.5
申请日：2017-10-11
摘要： The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.
-
-
公开(公告)号：EP3073996A1
公开(公告)日：2016-10-05
申请号：EP14802452.4
申请日：2014-11-25
发明人： KELTJENS, Rolf , EUPEN VAN, Jacobus Theodorus Henricus , RIETMAN, Bernard Herman , MURPANI, Deepak
CPC分类号： A61K9/2009 , A61K9/143 , A61K9/2077 , A61K31/55
摘要： The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of ivabradine, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.
摘要翻译： 本发明涉及药物组合物，其包含在多孔载体上的伊伐布雷定或其药学上可接受的盐的无定形吸附物和一种或多种药学上可接受的赋形剂。 本发明进一步涉及所述组合物作为药物的用途，特别是用于治疗稳定型心绞痛和慢性心力衰竭。
-
公开(公告)号：EP2948184A2
公开(公告)日：2015-12-02
申请号：EP15701106.5
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
IPC分类号： A61K47/48
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
-
公开(公告)号：EP2864346A1
公开(公告)日：2015-04-29
申请号：EP12728608.6
申请日：2012-06-21
发明人： KOKKE, Bastiaan Pieter Arian , VAN WIJK-BASTEN, Everdina Josephina Wilhelmina , DE BEIJER, Thomas Antonius Bernardus , EPPINK, Michel Hendrikus Maria , MARZÁ PÉREZ, Maria
IPC分类号： C07K1/36
CPC分类号： C07K1/36 , C07K1/18 , C07K1/34 , C07K16/065 , C07K16/32 , C07K2317/14
摘要： A method of purifying an antibody composition comprises application of anion exchange chromatography late in the purification process. An ultrafiltration/diafiltration-purified antibody composition is subjected to anion exchange chromatography (AEX) to form a pharmaceutically-pure antibody composition.
摘要翻译： 纯化抗体组合物的方法包括在纯化过程中晚期应用阴离子交换色谱法。 将超滤/渗滤纯化的抗体组合物进行阴离子交换层析（AEX）以形成药物纯的抗体组合物。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.016 秒)
